- Trellus Health
- 27 March 2026 16:04:51
Source: Sharecast
The AIM-traded firm said the agreement would see it deploy its TrialSet engagement tools to help improve trial site performance, while also enabling both parties to co-market services and access each other’s client bases.
It said the MSA would not generate immediate revenue, but provided a framework for future commercial opportunities and further validated its offering in the clinical trial sector.
Trellus added it was in advanced late-stage discussions regarding an additional clinical trial collaboration and would update the market in due course.
“This MSA with Gastro Health, alongside the recent extension of our collaboration with J&J and the continued roll-out of TrialSet across multiple clinical trials with our CRO partners, further supports the applicability of our platform and proprietary resilience methodology across the pharmaceutical lifecycle, from clinical development through to commercial deployment,” said chief executive Marla Dubinsky.
On funding, the company said it had reduced monthly cash burn to around $300,000 as of March and expected existing resources to last into early April.
It said it was in discussions regarding a potential loan from certain directors, while a convertible facility with Alumni Capital remained in place but is currently constrained by market conditions.
The board said it continued to support the company’s commercial strategy and was considering a range of funding options to extend its cash runway.
At 1148 GMT, shares in Trellus Health were down 23.64% at 0.21p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate